JP2018507244A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018507244A5 JP2018507244A5 JP2017546725A JP2017546725A JP2018507244A5 JP 2018507244 A5 JP2018507244 A5 JP 2018507244A5 JP 2017546725 A JP2017546725 A JP 2017546725A JP 2017546725 A JP2017546725 A JP 2017546725A JP 2018507244 A5 JP2018507244 A5 JP 2018507244A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- angiotensin
- receptor
- ace
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims 38
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims 12
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims 12
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims 12
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 8
- 108050000824 Angiotensin II receptor Proteins 0.000 claims 7
- 102000008873 Angiotensin II receptor Human genes 0.000 claims 7
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 claims 7
- 239000000018 receptor agonist Substances 0.000 claims 7
- 229940044601 receptor agonist Drugs 0.000 claims 7
- 239000003112 inhibitor Substances 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 5
- 229940002612 prodrug Drugs 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 3
- 102000015427 Angiotensins Human genes 0.000 claims 2
- 108010064733 Angiotensins Proteins 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- -1 ripiasartan Substances 0.000 claims 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims 2
- QIJLJZOGPPQCOG-NFAWXSAZSA-N (2s)-1-[(2s)-3-[(2r)-2-(cyclohexanecarbonylamino)propanoyl]sulfanyl-2-methylpropanoyl]pyrrolidine-2-carboxylic acid Chemical compound N([C@H](C)C(=O)SC[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(=O)C1CCCCC1 QIJLJZOGPPQCOG-NFAWXSAZSA-N 0.000 claims 1
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 claims 1
- SOYCBUUKISWFER-UHFFFAOYSA-N 2-[4-[[2-ethyl-4-methyl-6-(5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-2-yl)benzimidazol-1-yl]methyl]phenyl]benzoic acid Chemical compound CCC1=NC2=C(C)C=C(C=3N=C4CCCCN4C=3)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O SOYCBUUKISWFER-UHFFFAOYSA-N 0.000 claims 1
- 239000005485 Azilsartan Substances 0.000 claims 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 claims 1
- 239000002083 C09CA01 - Losartan Substances 0.000 claims 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 claims 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims 1
- 239000002081 C09CA05 - Tasosartan Substances 0.000 claims 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 claims 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 claims 1
- 108010061435 Enalapril Proteins 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 239000005475 Fimasartan Substances 0.000 claims 1
- 229940126043 Galectin-3 inhibitor Drugs 0.000 claims 1
- 108010007859 Lisinopril Proteins 0.000 claims 1
- 239000005474 Milfasartan Substances 0.000 claims 1
- 239000005480 Olmesartan Substances 0.000 claims 1
- 239000005473 Pomisartan Substances 0.000 claims 1
- 239000005477 Pratosartan Substances 0.000 claims 1
- 239000005478 Saprisartan Substances 0.000 claims 1
- DUEWVPTZCSAMNB-UHFFFAOYSA-N Saprisartan Chemical compound NC(=O)C=1N(CC=2C=C3C(Br)=C(OC3=CC=2)C=2C(=CC=CC=2)NS(=O)(=O)C(F)(F)F)C(CC)=NC=1C1CC1 DUEWVPTZCSAMNB-UHFFFAOYSA-N 0.000 claims 1
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 claims 1
- KGSXMPPBFPAXLY-UHFFFAOYSA-N azilsartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NOC(=O)N1 KGSXMPPBFPAXLY-UHFFFAOYSA-N 0.000 claims 1
- 229960002731 azilsartan Drugs 0.000 claims 1
- 229960004530 benazepril Drugs 0.000 claims 1
- XTEOJPUYZWEXFI-UHFFFAOYSA-N butyl n-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical group S1C(CC(C)C)=CC(C=2C=CC(CN3C=NC=C3)=CC=2)=C1S(=O)(=O)NC(=O)OCCCC XTEOJPUYZWEXFI-UHFFFAOYSA-N 0.000 claims 1
- 229960000932 candesartan Drugs 0.000 claims 1
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 claims 1
- 229960000830 captopril Drugs 0.000 claims 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical group SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960005025 cilazapril Drugs 0.000 claims 1
- HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229960000873 enalapril Drugs 0.000 claims 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims 1
- 229960004563 eprosartan Drugs 0.000 claims 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 229960003489 fimasartan Drugs 0.000 claims 1
- AMEROGPZOLAFBN-UHFFFAOYSA-N fimasartan Chemical compound CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 AMEROGPZOLAFBN-UHFFFAOYSA-N 0.000 claims 1
- 229960002490 fosinopril Drugs 0.000 claims 1
- 150000003840 hydrochlorides Chemical class 0.000 claims 1
- 229960001195 imidapril Drugs 0.000 claims 1
- KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 229960002198 irbesartan Drugs 0.000 claims 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims 1
- 229960002394 lisinopril Drugs 0.000 claims 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 claims 1
- 229960004773 losartan Drugs 0.000 claims 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical group CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims 1
- QVFVAKQHELFATN-UHFFFAOYSA-N methyl 2-[[4-butyl-2-methyl-6-oxo-5-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]pyrimidin-1-yl]methyl]thiophene-3-carboxylate Chemical compound O=C1C(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C2=NNN=N2)=C(CCCC)N=C(C)N1CC=1SC=CC=1C(=O)OC QVFVAKQHELFATN-UHFFFAOYSA-N 0.000 claims 1
- 229950003561 milfasartan Drugs 0.000 claims 1
- 229950006549 moveltipril Drugs 0.000 claims 1
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 claims 1
- 229960004378 nintedanib Drugs 0.000 claims 1
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 claims 1
- 229960005117 olmesartan Drugs 0.000 claims 1
- 229960002582 perindopril Drugs 0.000 claims 1
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 claims 1
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 claims 1
- 229960003073 pirfenidone Drugs 0.000 claims 1
- 229950004971 pomisartan Drugs 0.000 claims 1
- KCTFTBCZZUBAKN-UHFFFAOYSA-N pratosartan Chemical compound CCCC1=NC=2CCCCC(=O)C=2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 KCTFTBCZZUBAKN-UHFFFAOYSA-N 0.000 claims 1
- 229950005649 pratosartan Drugs 0.000 claims 1
- 229960001455 quinapril Drugs 0.000 claims 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 claims 1
- 229960003401 ramipril Drugs 0.000 claims 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 claims 1
- 229950006241 saprisartan Drugs 0.000 claims 1
- 229960002909 spirapril Drugs 0.000 claims 1
- 108700035424 spirapril Proteins 0.000 claims 1
- HRWCVUIFMSZDJS-SZMVWBNQSA-N spirapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2(C1)SCCS2)C(O)=O)CC1=CC=CC=C1 HRWCVUIFMSZDJS-SZMVWBNQSA-N 0.000 claims 1
- 229960000651 tasosartan Drugs 0.000 claims 1
- ADXGNEYLLLSOAR-UHFFFAOYSA-N tasosartan Chemical compound C12=NC(C)=NC(C)=C2CCC(=O)N1CC(C=C1)=CC=C1C1=CC=CC=C1C=1N=NNN=1 ADXGNEYLLLSOAR-UHFFFAOYSA-N 0.000 claims 1
- 229960005187 telmisartan Drugs 0.000 claims 1
- 229960002051 trandolapril Drugs 0.000 claims 1
- 229960004699 valsartan Drugs 0.000 claims 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims 1
- 229960002769 zofenopril Drugs 0.000 claims 1
- IAIDUHCBNLFXEF-MNEFBYGVSA-N zofenopril Chemical compound C([C@@H](C)C(=O)N1[C@@H](C[C@@H](C1)SC=1C=CC=CC=1)C(O)=O)SC(=O)C1=CC=CC=C1 IAIDUHCBNLFXEF-MNEFBYGVSA-N 0.000 claims 1
Claims (22)
- 肺線維症の治療のための、アンギオテンシンＩＩ受容体作動薬、またはその薬学的に許容される塩、溶媒和化合物、もしくはプロドラッグを含む組成物。
- 前記アンギオテンシンＩＩ受容体作動薬が、アンギオテンシンＩＩ２型（ＡＴ２）受容体の選択的作動薬、またはその薬学的に許容される塩、溶媒和化合物、もしくはプロドラッグである、請求項１に記載の組成物。
- アンギオテンシンＩＩ２型（ＡＴ２）受容体の選択的作動薬が、非ペプチド性選択的作動薬、またはその薬学的に許容される塩、溶媒和化合物、もしくはプロドラッグである、請求項２に記載の組成物。
- 前記アンギオテンシンＩＩ受容体作動薬が、Ｎ−ブチルオキシカルボニル−３−（４−イミダゾール−１−イルメチルフェニル）−５−イソ−ブチルチオフェン−２−スルホンアミド（Ｃ２１）、またはその薬学的に許容される塩、任意にＨＣｌ塩、溶媒和化合物、もしくはプロドラッグである、請求項１〜３のいずれか一項に記載の組成物。
- 前記肺線維症が特発性肺線維症である、請求項１〜４のいずれか一項に記載の組成物。
- 前記投与することが、経鼻的に、経口的に、非経口的に、または吸入により前記組成物を前記対象に導入することを含む、請求項１〜５のいずれか一項に記載の組成物。
- 前記組成物が、２つ以上の投与経路を介して別個に、順次に、及び／または同時に投与される、請求項１〜６のいずれか一項に記載の組成物。
- 投与経路の組み合わせが吸入及び経口である、請求項７に記載の組成物。
- 前記組成物が、約０．３〜約１００ｍｇの範囲の１日用量で対象に投与される、請求項１〜８のいずれか一項に記載の組成物。
- 前記組成物が、ＡＴ１受容体拮抗薬と組み合わせて投与される、請求項１〜９のいずれか一項に記載の組成物。
- 前記ＡＴ１受容体拮抗薬が、ロサルタン、アジルサルタン、カンデサルタン、エプロサルタン、フィマサルタン、イルベサルタン、ミルファサルタン、オルメサルタン、ポミサルタン、プラトサルタン、リピアサルタン（ｒｉｐｉａｓａｒｔａｎ）、サプリサルタン、タソサルタン、テルミサルタン、バルサルタン、及びそれらの組み合わせからなる群より選択される、請求項１０に記載の組成物。
- 前記組成物及び前記ＡＴ１受容体拮抗薬が、別個に、順次に、及び／または同時に投与される、請求項１０または請求項１１に記載の組成物。
- 前記ＡＴ１受容体拮抗薬が、前記アンギオテンシンＩＩ受容体作動薬を含む前記組成物と同じ組成物内または別個の組成物内に提供される、請求項１０〜１２のいずれか一項に記載の組成物。
- 前記組成物が、アンギオテンシン変換酵素（ＡＣＥ）の阻害薬と組み合わせて投与される、請求項１〜１３のいずれか一項に記載の組成物。
- 前記アンギオテンシン変換酵素（ＡＣＥ）阻害薬が、カプトプリル、ゾフェノプリル、エナラプリル、ラミプリル、キナプリル、ペリンドプリル、リシノプリル、ベナゼプリル、イミダプリル、トランドラプリル、ホシノプリル、モエキシプリル、シラザプリル、スピラプリル、テモカプリル、アラセプリル、セロナプリル、デレプリル（ｄｅｌｅｐｒｉｌ）、モベルチプリル、及びそれらの組み合わせからなる群より選択される、請求項１４に記載の組成物。
- 前記組成物及び前記アンギオテンシン変換酵素（ＡＣＥ）阻害薬が、別個に、順次に、及び／または同時に投与される、請求項１５または請求項１５に記載の組成物。
- 前記アンギオテンシン変換酵素（ＡＣＥ）の阻害薬が、前記アンギオテンシンＩＩ受容体作動薬を含む前記組成物と同じ組成物内または別個の組成物内に提供される、請求項１４〜１６のいずれか一項に記載の組成物。
- 前記組成物が、ＡＴ１受容体拮抗薬及びアンギオテンシン変換酵素（ＡＣＥ）阻害薬と組み合わせて投与される、請求項１〜１７のいずれか一項に記載の組成物。
- 前記ＡＴ１受容体拮抗薬及び前記アンギオテンシン変換酵素（ＡＣＥ）阻害薬が、互いに別個に、順次に、及び／または同時に投与される、請求項１８に記載の組成物。
- 前記ＡＴ１受容体拮抗薬及び前記アンギオテンシン変換酵素（ＡＣＥ）阻害薬が、前記アンギオテンシンＩＩ受容体作動薬を含む前記組成物と同じ組成物内に提供される、請求項１８に記載の組成物。
- 前記ＡＴ１受容体拮抗薬及び前記アンギオテンシン変換酵素（ＡＣＥ）阻害薬が、互い及び／または前記アンギオテンシンＩＩ受容体作動薬を含む前記組成物とは別個の組成物内に提供される、請求項１９または請求項２０に記載の組成物。
- 前記組成物が、ガレクチン−３阻害薬、またはＩＰＦもしくは線維症関連疾病のための１つ以上の確立された治療薬と組み合わせて投与され、任意に、前記１つ以上の確立された治療薬が、ピルフェニドン及びニンテダニブからなる群より選択される薬剤を含む、請求項１〜９のいずれか一項に記載の組成物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562126880P | 2015-03-02 | 2015-03-02 | |
| US62/126,880 | 2015-03-02 | ||
| PCT/GB2016/050552 WO2016139475A1 (en) | 2015-03-02 | 2016-03-02 | Angiotensin ii receptor agonist for treating pulmonary fibrosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018507244A JP2018507244A (ja) | 2018-03-15 |
| JP2018507244A5 true JP2018507244A5 (ja) | 2019-04-04 |
Family
ID=55646777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017546725A Withdrawn JP2018507244A (ja) | 2015-03-02 | 2016-03-02 | 肺線維症の治療のためのアンギオテンシンｉｉ受容体作動薬 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20180078529A1 (ja) |
| EP (1) | EP3265082A1 (ja) |
| JP (1) | JP2018507244A (ja) |
| KR (1) | KR20170122754A (ja) |
| CN (1) | CN107405406A (ja) |
| AU (1) | AU2016227486A1 (ja) |
| BR (1) | BR112017018715A2 (ja) |
| CA (1) | CA2977445A1 (ja) |
| HK (1) | HK1244232A1 (ja) |
| MX (1) | MX2017010993A (ja) |
| WO (1) | WO2016139475A1 (ja) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7418587B2 (ja) | 2020-04-24 | 2024-01-19 | ヴィコール ファルマ アーベー | 経口投与用の新しい遅延放出組成物 |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017204163A1 (ja) * | 2016-05-23 | 2017-11-30 | 国立研究開発法人国立循環器病研究センター | 肺障害の予防または抑制用医薬 |
| WO2019014710A1 (en) * | 2017-07-17 | 2019-01-24 | Monash University | ANGIOTENSIN RECEPTOR AGONISTS AND USES THEREOF |
| EP3820498A1 (en) | 2018-06-14 | 2021-05-19 | University College Cork-National University of Ireland Cork | Peptide for disease treatment |
| GB201818164D0 (en) | 2018-11-07 | 2018-12-19 | Vicore Pharma Ab | New composition |
| GB201913603D0 (en) | 2019-09-20 | 2019-11-06 | Vicore Pharma Ab | New compounds |
| GB201917327D0 (en) | 2019-11-28 | 2020-01-15 | Vicore Pharma Ab | New pharmaceutical use |
| AU2021238939A1 (en) | 2020-03-19 | 2022-11-10 | Vicore Pharma Ab | Novel compounds useful in the treatment and/or prevention of a disease, disorder or condition associated with angiotensin II |
| GB202004094D0 (en) | 2020-03-20 | 2020-05-06 | Vicore Pharma Ab | New compounds and uses |
| US11123329B1 (en) | 2020-03-23 | 2021-09-21 | Vicore Pharma Ab | Use of angiotensin II type 2 receptor agonist |
| GB202006079D0 (en) | 2020-04-24 | 2020-06-10 | Vicore Pharma Ab | New composition |
| GB202006081D0 (en) | 2020-04-24 | 2020-06-10 | Vicore Pharma Ab | New composition |
| GB202007122D0 (en) | 2020-05-14 | 2020-07-01 | Vicore Pharma Ab | New process |
| GB202013721D0 (en) | 2020-09-01 | 2020-10-14 | Vicore Pharma Ab | New compounds |
| GB202104038D0 (en) | 2021-03-23 | 2021-05-05 | Vicore Pharma Ab | New compounds |
| GB202104033D0 (en) | 2021-03-23 | 2021-05-05 | Vicore Pharma Ab | New compounds |
| WO2022200785A1 (en) | 2021-03-23 | 2022-09-29 | Vicore Pharma Ab | Selective angiotensin ii receptor ligands |
| AU2022306778A1 (en) | 2021-07-09 | 2024-01-18 | Vicore Pharma Ab | New selective angiotensin ii compounds |
| GB202115303D0 (en) | 2021-10-25 | 2021-12-08 | Vicore Pharma Ab | New formulation |
| WO2023140350A1 (ja) * | 2022-01-21 | 2023-07-27 | 国立大学法人 長崎大学 | 臓器の線維化抑制用医薬組成物 |
| GB202201723D0 (en) | 2022-02-10 | 2022-03-30 | Vicore Pharma Ab | New use |
| WO2023152503A1 (en) | 2022-02-10 | 2023-08-17 | Vicore Pharma Ab | Use of buloxibutid for the treatment of idiopathic pulmonary fibrosis |
| CN114869866B (zh) * | 2022-05-05 | 2024-02-20 | 珠海瑞思普利医药科技有限公司 | 一种治疗特发性肺纤维化的干粉吸入剂及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9800550D0 (sv) | 1998-02-24 | 1998-02-24 | A & Science Invest Ab | A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof |
| US20030113330A1 (en) * | 1999-11-08 | 2003-06-19 | Uhal Bruce D. | Methods for treating pulmonary fibrosis |
| DE60222409T2 (de) | 2001-05-31 | 2008-09-25 | Vicore Pharma Ab | Trizyklische verbindungen, nützlich als angiotensin ii agonisten |
| US8835471B2 (en) * | 2010-06-11 | 2014-09-16 | Vicore Pharma Ab | Use of angiotensin II agonists |
| EP2832357A1 (en) * | 2013-07-29 | 2015-02-04 | Charité - Universitätsmedizin Berlin | Selective AT2 receptor agonists for use in treatment of cachexia |
-
2016
- 2016-03-02 CN CN201680012711.8A patent/CN107405406A/zh not_active Withdrawn
- 2016-03-02 US US15/554,213 patent/US20180078529A1/en not_active Abandoned
- 2016-03-02 BR BR112017018715-9A patent/BR112017018715A2/pt active Search and Examination
- 2016-03-02 MX MX2017010993A patent/MX2017010993A/es unknown
- 2016-03-02 AU AU2016227486A patent/AU2016227486A1/en not_active Withdrawn
- 2016-03-02 JP JP2017546725A patent/JP2018507244A/ja not_active Withdrawn
- 2016-03-02 WO PCT/GB2016/050552 patent/WO2016139475A1/en active Application Filing
- 2016-03-02 KR KR1020177023949A patent/KR20170122754A/ko not_active Application Discontinuation
- 2016-03-02 CA CA2977445A patent/CA2977445A1/en not_active Withdrawn
- 2016-03-02 EP EP16712990.7A patent/EP3265082A1/en not_active Withdrawn
-
2018
- 2018-03-20 HK HK18103826.4A patent/HK1244232A1/zh unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7418587B2 (ja) | 2020-04-24 | 2024-01-19 | ヴィコール ファルマ アーベー | 経口投与用の新しい遅延放出組成物 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018507244A5 (ja) | ||
| JP2014505049A5 (ja) | ||
| WO2008133896A3 (en) | Dual-acting antihypertensive agents | |
| JP2019501935A5 (ja) | ||
| HRP20180319T1 (hr) | Predlijek adrenomedulina baziran na polietilen glikolu i njegova uporaba | |
| MX2011011428A (es) | Derivados de acido sulfamoilbenzoico como antagonistas de trpm8. | |
| HRP20110969T4 (hr) | Pimobendan za upotrebu za smanjenje veličine srca kod sisavaca koji pate od srčane insuficijencije | |
| MY160728A (en) | Morpholinothiazoles as alpha 7 positive allosteric modulators | |
| EP2328414A4 (en) | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES | |
| WO2005082893A3 (en) | Histamine h3 receptor antagonists, preparation and therapeutic uses | |
| MX2014005075A (es) | Formulaciones de sal de meglumina del acido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxilico. | |
| UA107353C2 (en) | Salts of bicyclo-substituted pyrazolon azo derivatives, preparation method and use thereof | |
| JP2013518914A5 (ja) | ||
| NZ609533A (en) | Angiotensin ii receptor antagonist for the prevention or treatment of systemic diseases in cats | |
| RU2015110979A (ru) | Комбинации ингибиторов sglt 2 и антигипертензивных лекарственных средств | |
| US10016397B2 (en) | Selective AT2 receptor agonists for use in treatment of cachexia | |
| JP2016520135A5 (ja) | ||
| AR096350A1 (es) | Composición farmacéutica para administración por vía oral para su uso para la prevención y/o el tratamiento de una enfermedad cardiovascular | |
| HRP20170267T1 (hr) | Kombinacija (3s,3s') 4,4'-disulfandiilbis(3-aminobutan 1-sulfonske kiseline) i drugog antihipertenzivnog agensa | |
| AR068814A1 (es) | Composicion farmaceutica que comprende levosimendan y un inhibidor de la enzima conversina de la angiotensina (ace), y uso | |
| WO2009081246A3 (en) | Bicyclic diamines as nicotinic receptor agonists | |
| NZ603414A (en) | Association of xanthine oxidase inhibitors and angiotensin ii receptor antagonists and use thereof | |
| WO2011094208A3 (en) | Methods and pharmaceutical compositions for preventing and treating renal impairment | |
| WO2004098611A1 (ja) | 増強剤 | |
| NZ589904A (en) | Eprosartan compositions |